ChatGPTを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。この１年、病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
<>
24/04/11
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials
S MacIsaac, D Somboonviboon, C Scallan, M Kolb - Expert Opinion on Emerging …, 2024
… This review highlights the current landscape of IPF research in the development of novel compounds for the treatment IPF while also evaluating repurposed medications and their role in the management of IPF. The literature search includes …
- 特発性肺線維症の治療：第 II 相および第 III 相臨床試験中の新薬に関する最新情報
Revolutionizing the Treatment of Idiopathic Pulmonary Fibrosis: From Conventional Therapies to Advanced Drug Delivery Systems
S Singh, S Wairkar - AAPS PharmSciTech, 2024
… This article elaborates on the pathophysiology of IPF, its risk factors, and different advanced drug delivery systems for treating IPF. … IPF. This article comprehensively reviews different drugs and their novel delivery systems reported for treating …
- 特発性肺線維症の治療に革命を起こす：従来の治療法から先進的な薬物送達システムまで
Shengxian decoction improves lung function in rats with bleomycin-induced idiopathic pulmonary fibrosis through the inhibition of PANoptosis
Y Liang, Y Yan, N Liu, J Wang, C Fang - Journal of Ethnopharmacology, 2024
… to observe PANoptosis in bleomycin-induced IPF and to assess the efficacy and mechanism of action of SXD in the treatment of IPF. … In this study, bleomycin was used to induce idiopathicfibrosis in rats to observe whether PANoptosis occurs …
- Shengxian煎じ薬は、PANoptosisの阻害を通じてブレオマイシン誘発性特発性肺線維症のラットの肺機能を改善します
[HTML] Identification of idiopathic pulmonary fibrosis hub genes and exploration of the mechanisms of action of Jinshui Huanxian formula
Q Guan, Z Zhang, P Zhao, L Huang, R Lu, C Liu… - International …, 2024
… , and identified individualized DEGs and the common DEGs for IPF. Through the protein–protein interaction (PPI) network analysis and RNA-seq data of mice with pulmonary fibrosis(PF) measured by our laboratory, IPF hub genes were identified …
- 特発性肺線維症ハブ遺伝子の同定とJinshui Huanxian処方の作用機序の探索
[PDF] The Analysis of Proteomics by Machine Learning in Separating Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Interstitial Lung Disease
Y Moodley - American Journal of Respiratory and Critical Care …, 2024
… may be (mis)-classified as IPF. This scenario can lead the MDD to reclassify IPF to a fibrosing CTD-ILD when the full clinical and serology picture unveils itself. Furthermore, proteomic comparisons between fibrosing CTD-ILD and IPFmight also …
- 特発性肺線維症と結合組織病-間質性肺疾患の分離における機械学習によるプロテオミクス解析
[HTML] NBR1-p62-Nrf2 mediates the anti-pulmonary fibrosis effects of protodioscin
Q Zeng, B Wen, X Liu, Y Luo, Z Hu, L Huang, X Zhang… - Chinese Medicine, 2024
… Idiopathic pulmonary fibrosis is a persistent disease of the lung interstitium for which there is no efficacious pharmacological therapy. … in pulmonary fibrosis is yet to be established. Hence, in this investigation, it was attempted to figure out the anti-pulmonary …
- NBR1-p62-Nrf2 はプロトジオシンの抗肺線維症効果を媒介します
Exploring the selective inhibition of post-translational lysine modifier enzymes: toward new therapeutic approaches for rare disorders
A Fontana - 2024
… idiopathic pulmonary fibrosis (IPF), and retinitis pigmentosa (RP,) (ii), inflammation-based pathologies and (iii) cancer. To identify new pharmacological tools against IPF, … THIQ and spiro-THIQ analogues were revealed effective in attenuating IPF-related …
- 翻訳後リジン修飾酵素の選択的阻害の探索：希少疾患に対する新たな治療アプローチに向けて
Characterization Of Pirfenidone Effects In Human Cardiac Fibroblasts
F Meyer - 2024
… The drug pirfenidone has shown several anti-fibrotic effects in animal models of heart diseases and is already approved for the treatment of idiopathic pulmonary fibrosis. This led to the hypothesis that pirfenidone could have beneficial effects as …
- ヒト心臓線維芽細胞におけるピルフェニドンの効果の特性評価
24/04/08
[PDF] Eating and drinking experience in patients with idiopathic pulmonary fibrosis: a qualitative study
AA Alamer, C Ward, I Forrest, M Drinnan, J Patterson - BMJ Open, 2024
… Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease characterised by unknown causes. It is primarily … Typical symptoms of IPF include chronic exertional dyspnoea and a persistent dry cough.2 Risk factors for …
- 特発性肺線維症患者の飲食経験：定性的研究
[PDF] Anxiety and depression status in patients with idiopathic pulmonary fibrosis and outcomes of nintedanib treatment: an observational study
X He, J Ji, Z Pei, Z Luo, S Fang, X Liu, Y Lei, H Yan… - Annals of Medicine, 2024
… Anxiety and depression are common comorbidities in idiopathic pulmonary fibrosis(IPF) that impair health-related quality of life. However, there is a lack of studies focusing on the mental disorder of IPF after antifibrotic treatment and their …
- 特発性肺線維症患者の不安とうつ病の状態とニンテダニブ治療の結果：観察研究
[HTML] … Adhesion Molecule–1 Expression Increases in the Small Airway Epithelium and Parenchyma of Patients with Idiopathic Pulmonary Fibrosis: Implications for Microbial …
AM Shahzad, W Lu, S Dey, P Bhattarai, AV Gaikwad… - Journal of Clinical Medicine, 2024
… Background: Idiopathic pulmonary fibrosis(IPF) is an irreversible lung fibrotic disorder of … Methods: Immunohistochemical staining was carried out for lung resections from IPF patients (n … and alveolar macrophages was higher in IPF than …
- 特発性肺線維症患者の小気道上皮および実質における血小板活性化因子受容体および細胞間接着分子-1の発現増加：微生物の病因への影響
[PDF] Causality between cathepsins and idiopathic pulmonary fibrosis: a Mendelian randomization study
Z Zhong, R Xu, C Xu, Y Zhu, Q Xu, Y Hua - 2024
… on IPF and may serve as a potential therapeutic target for IPF, providing inspiration and guidance for the diagnosis and treatment of IPF. … cathepsin H reduces the risk of developing IPF and may serve as a potential therapeutic target …
- カテプシンと特発性肺線維症との因果関係: メンデルランダム化研究
IMPACT OF IDIOPATHIC PULMONARY FIBROSIS ON OUTCOMES OF ACUTE MYOCARDIAL INFARCTION: INSIGHTS FROM THE NATIONAL INPATIENT DATA
S Kansakar, S Shikhrakar, A Basnet, S Gautam… - Journal of the American …, 2024
… Idiopathic Pulmonary Fibrosis (IPF), share common risk factors and pathophysiological pathways with acute myocardial infarction (AMI). However, there is a scarcity of data regarding the influence of IPF … diagnosis of AMI with and …
[HTML] Selenite selectively kills lung fibroblasts to treat bleomycin-induced pulmonary fibrosis
JH Lin, CC Liu, CY Liu, TW Hsu, YC Yeh, CK How… - Redox Biology, 2024
… The aetiologies of ILD include smoking, hypersensitivity, and chronic viral infections, and most cases are idiopathic. Idiopathicpulmonary fibrosis (IPF) is considered the most important and severe subtype of ILD because its morbidity and …
- 亜セレン酸は肺線維芽細胞を選択的に殺し、ブレオマイシン誘発性肺線維症を治療します
[HTML] IL20Rb aggravates pulmonary fibrosis through enhancing bone marrow derived profibrotic macrophage activation
J Zhu, Q Jiang, S Gao, Q Xia, H Zhang, B Liu, R Zhao… - Pharmacological Research, 2024
… IPF, we examined the expression of IL20, the ligand of IL20Rb, in the serum of IPF patients, and as expected, IL20 was highly expressed in the serum of IPF … silencing IL20Rb in macrophages may be a potential clinical strategy for the …
- IL20Rbは骨髄由来の線維化促進性マクロファージの活性化を促進することで肺線維症を悪化させる
Tacrolimus alleviates pulmonary fibrosis progression through inhibiting the activation and interaction of ILC2 and monocytes
B Liu, Q Jiang, R Chen, H Zhang, Q Xia, C Shao, X Liu… - International …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a heterogeneous group of lung diseases with different etiologies and characterized by progressive fibrosis. This disease usually causes pulmonary structural remodeling and decreased pulmonary function …
- タクロリムスは、ILC2 と単球の活性化と相互作用を阻害することで肺線維症の進行を緩和します
Drug discovery by AI trained on aging biology
S Thuault - Nature Aging, 2024
… Fibrotic diseases (such as idiopathicpulmonary fibrosis (IPF) and chronic kidney disease), which are usually associated with old age, are … leverages a multistage generative artificial intelligence (AI) platform to identify and validate a small-molecule …
- 老化生物学を学習したAIによる創薬
[PDF] IPF-related new macrophage subpopulations and diagnostic biomarker identification-combine machine learning with single-cell analysis
H Zhang, Y Yang, Y Cao, J Guan - 2024
… Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease with an unknown etiology and lacks speci c treatment. Macrophages, as a major … 8 IPF patients, we revealed distinct macrophage subtypes in IPF lung tissue. In this study, we identi ed a …
- IPF関連の新しいマクロファージ亜集団と診断用バイオマーカーの同定 - 機械学習と単一細胞解析を組み合わせる
24/04/07
Incidence, etiology, and outcome of hospital-acquired pneumonia in patients with acute exacerbation of fibrotic idiopathic interstitial pneumonia
R Yamazaki, O Nishiyama, K Yosikawa, K Gose… - Respiratory Investigation, 2024
… with idiopathic pulmonary fibrosis [IPF] and 39 with non-IPF fIIP) who were hospitalized a total of 155 times (111 with IPF and 44 with non-IPF … Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease (ILD) of …
[PDF] “A Mighty Flame Can Follow a Tiny Spark”: Is This the Case of C-Jun N-Terminal Kinase 1 (JNK) Inhibitors in Idiopathic Pulmonary Fibrosis?
F Luppi, G Ferrara - American Journal of Respiratory and Critical Care …, 2024
… Idiopathic pulmonary fibrosis (IPF) is a rare and devastating disease causing irreversible … able to show any efficacy of the new drugs for IPF over the control groups. All the recent RCTs … Although the clinical need is important, since at least …
- 「強力な炎は小さな火花に続くことがある」：これは特発性肺線維症における C-Jun N 末端キナーゼ 1 (JNK) 阻害剤の場合ですか?
[PDF] O-GlcNAc Transferase Regulates Collagen Deposition and Fibrosis Resolution in Idiopathic
S Vang, ES Helton, Y Guo, B Burpee, E Rose, M Easter… - Frontiers in Immunology
… Background Idiopathic pulmonary fibrosis(IPF) is a chronic pulmonary disease that is 24 characterized by an excessive accumulation of extracellular matrix (ECM) proteins (ie collagens) 25 in the parenchyma, which ultimately leads to respiratory …
- O-GlcNAc トランスフェラーゼは特発性患者のコラーゲン沈着と線維症の解消を制御する
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine
A Adegunsoye, JA Kropski, J Behr, TS Blackwell… - American Journal of …, 2024
… into the risk factors for and mechanisms that mediate idiopathic pulmonary fibrosis (IPF) … five novel loci associated with idiopathicpulmonary fibrosis. Thorax 2022; 77: 829-833. … Idiopathic pulmonary fibrosis: a composite physiologic index …
- 肺線維症の遺伝学とゲノミクス: 分子状況の図表と精密医療の形成
Pulmonary Fibrosis and Diabetes Mellitus: Two coins with the same face
YM Mari, MP Fraix, DK Agrawal - Archives of internal medicine research, 2024
… Idiopathic pulmonary fibrosis (IPF) constitutes a long-term disease with a complex pathophysiology composed of multiple molecular actors … One of the risk factors for the development of IPF is the pre-existing condition of diabetes mellitus. Both, IPF …
- 肺線維症と糖尿病: 同じ顔の 2 枚のコイン
[PDF] pre-existing interstitial lung disease: A literature review and future perspectives
M Hanibuchi, H Ogino, S Sato, Y Nishioka - The Journal of Medical Investigation, 2024
… Idiopathic pulmonary fibrosis (IPF) is one of the most common ILDs. The incidence of LC comorbidity with IPF is generally considered to be approximately 10-20% (2). The greatest concern in LC-ILD is acute exacerbation (AE) of ILD (AE-ILD) …
- 既存の間質性肺疾患：文献レビューと将来の展望
Proteome-wide Mendelian randomization identifies causal plasma proteins in Interstitial lung disease
K Yu, W Li, W Long, Y Li, Y Li, H Liao, J Liu - 2024
… Interstitial lung disease (ILD) has exhibited limited overall treatment advancements, with scant exploration into circulating protein biomarkers causally linked to ILD and its subtypes beyond idiopathic pulmonary fibrosis(IPF). Therefore …
- プロテオーム全体のメンデルランダム化により、間質性肺疾患の原因となる血漿タンパク質が特定される
24/04/06
TAPSE/SPAP ratio stratifies mortality risk in mild-to-moderate idiopathic pulmonary fibrosis
A Sonaglioni, A Caminati, E Grasso, M Colleoni… - The International Journal of …, 2024
… idiopathic pulmonary fibrosis (IPF) patients without severe pulmonary hypertension and at assessing its correlation with effective arterial elastance index (EaI). METHODS: Multi-instrumental data obtained in 60 IPF … was significantly lower in …
- TAPSE/SPAP比は軽度から中等度の特発性肺線維症における死亡リスクを層別化する
Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with “idiopathic” interstitial lung disease
SL Tansley, F McMorrow, CV Cotton, H Adamali… - Clinical Immunology, 2024
… Randomly selected serum samples from three patient subtypes of ILD (as diagnosed by their local respiratory medicine teams) were analysed: 251 patients with of idiopathic pulmonaryfibrosis (IPF), 206 with idiopathic non-specific interstitial …
Infectious respiratory pathogens among patients with acute exacerbation of idiopathic pulmonary fibrosis during the coronavirus disease 2019 pandemic in Japan
K Akata, K Yamasaki, T Kawaguchi, Y Chiba, K Sennari… - Heart & Lung, 2024
… with acute exacerbation of idiopathicpulmonary fibrosis (AE-IPF), specifically, the interactions between respiratory pathogens and AE-IPF during the … Idiopathic pulmonaryfibrosis (IPF) is a progressive fibrotic lung disease of unknown etiology. It …
Association between statin use and the risk for idiopathic pulmonary fibrosis and its prognosis: a nationwide, population-based study
J Park, CH Lee, K Han, SM Choi - Scientific reports, 2024
… A case-control study was performed to evaluate the association between statin use and the risk for IPF, and the multivariable analysis revealed that statin use was associated with a lower risk for IPF (adjusted OR 0.847, 95% CI 0.800-0.898). Using …
- スタチン使用と特発性肺線維症のリスクおよびその予後の関連性：全国的な集団ベースの研究
407 The OGT/O-GlcNAc Axis Regulates Fibrosis Resolution in Idiopathic Pulmonary Fibrosis
S Vang, Y Livelo, B Burpee, MJ Hirsch, EL Matthews… - Journal of Clinical and …, 2024
… Lastly, a mouse model of bleomycin-induced pulmonary fibrosis was examined following … -GlcNAc staining was increased in IPF lung tissue compared to non-IPF control lungs. In primary … in pulmonary fibrosis, and we show that O-GlcNAc is …
- OGT/O-GlcNAc 軸は特発性肺線維症における線維症の解消を制御する
Interstitial Lung Abnormalities (ILA) and Pulmonary Fibrosis
N Wada, KS Lee, H Hatabu - Current Pulmonology Reports, 2024
… In a series of studies, ILA and pulmonaryfibrosis, especially idiopathic pulmonaryfibrosis (IPF), have been shown to potentially share common clinical, biological, physiological, radiological, and histopathological features, and thus they have …
- 間質性肺異常 (ILA) と肺線維症
[HTML] NR2F2 alleviates pulmonary fibrosis by inhibition of epithelial cell senescence
R Wan, S Long, S Ma, P Yan, Z Li, K Xu, H Lian, W Li… - Respiratory Research, 2024
… IPF lung tissues and control non-IPF lung tissue samples were recruited based on the ATS/ERS/JRS/ALAT Clinical Practice Guidelines at Henan Provincial Chest Hospital. The study was approved by the Henan Provincial Chest Hospital Medical …
- NR2F2は上皮細胞の老化を阻害することで肺線維症を軽減します
ESL Attenuates BLM-induced IPF in Mice: Dual Mediation of the TLR4/NF-κB and TGF-β1/PI3K/Akt/FOXO3a Pathways
C Jia, M Yang, G Xiao, Z Zeng, L Li, Y Li, J Jiang, A Xu… - Phytomedicine, 2024
… Idiopathic pulmonary fibrosis (IPF) is a persistent and advanced pulmonary ailment. The roles of innate immunity and adaptive immunity … potential mechanism underlying the anti-IPFeffect of ESL. BLM-induced IPF mice were used to validate …
- ESLはマウスのBLM誘発性IPFを軽減する：TLR4/NF-κBおよびTGF-β1/PI3K/Akt/FOXO3a経路の二重媒介
[HTML] A WNT mimetic with broad spectrum FZD-specificity decreases fibrosis and improves function in a pulmonary damage model
M Patel, Y Post, N Hill, A Sura, J Ye, T Fisher, N Suen… - Respiratory Research, 2024
… Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by areas of myofibroblast accumulation and extracellular matrix (ECM) deposition, disruption of alveolar architecture, and restricted lung physiology [1,2,3]. The median …
- 広範囲のFZD特異性を持つWNT模倣物は線維症を減少させ、肺損傷モデルの機能を改善する
[HTML] The effect of antifibrotic agents on acute respiratory failure in COVID-19 patients: a retrospective cohort study from TriNetX US collaborative networks
HY Wang, SC Tsai, YC Lin, JU Hou, CH Chao - BMC Pulmonary Medicine, 2024
… Novel antifibrotic agents such as nintedanib and pirfenidone have demonstrated effectiveness in managing patients with idiopathic pulmonaryfibrosis (IPF). Nintedanib functions as an intracellular inhibitor targeting vascular endothelial …
<>
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
